Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kelch-like protein 5 (KLHL5) is a member of the kelch superfamily, characterized by BTB, BACK, and kelch repeat domains, which enable it to function as a substrate adaptor in Cullin-3 (CUL3)-based E3 ubiquitin ligase complexes. KLHL5 binding targets specific proteins for ubiquitination and degradation and is involved in regulating the actin cytoskeleton, cell morphology, and cell cycle progression. It is broadly expressed across benign and malignant tissues, with dysregulated expression in multiple cancer types; higher expression is often associated with poor prognosis, especially in gastric cancer, where it additionally modulates immune cell infiltration. KLHL5 knockdown in vitro increases cellular sensitivity to a variety of anticancer drugs, indicating potential as a therapeutic target or modulator of drug response. Its molecular function and interactors beyond CUL3 complexes remain incompletely characterized.
Modulates cell cycle and protein degradation (likely affecting cell survival and drug sensitivity in cancer context)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kelch-like protein 5 (KLHL5).